

DEC 18 2007

PTQ/SB/08A (04-07)

Approved for use through 09/30/2007 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

**Complete if Known**

Application Number	10/559,639
Filing Date	July 24, 2006
First Named Inventor	Dina BEN-YEHUDA
Art Unit	1647
Examiner Name	Elly Gerald STOICA
Attorney Docket Number	7640-X06-046

Sheet	1	of	7
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

[illegible]

Examiner Signature	/Elly Gerald Stoica/	Date Considered	05/20/2008
-----------------------	----------------------	--------------------	------------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPC Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.G.S./



DEC 18 2007

Approved for use through 09/30/2007. OMB 0551-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2

of

7

## **Complete if Known**

Application Number	10/559,639
Filing Date	July 24, 2006
First Named Inventor	Dina BEN-YEHUDA
Art Unit	1647
Examiner Name	Ely Gerald STOICA
Attorney Docket Number	7640-X06-046

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AC	YAQOUB ASHHAB et al., Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern, FEBS Letters, 2001, Vol. 495, pp. 56-60.	
	AD	XUETAO CAO et al., Lymphotactin Gene-Modified Bone Marrow Dendritic Cells Act as More Potent Adjuvants for Peptide Delivery to Induce Specific Antitumor Immunity, The Journal of Immunology, 1998, Vol. 161, pp. 6238-6244.	
	AE	JIJIE CHAI et al., Structural Basis of Caspase-7 Inhibition by XIAP, Cell March 9, 2001, Vol. 104, pp. 769-780.	
	AF	CROZET Y. et al., Synthesis and characterization of cyclic pseudopeptide libraries containing thiomethylene and thiomethylenesulfoxide amide bond surrogates, Mol Divers, 1997-1998, Vol. 3, No. 4, pp. 261-276.	
	AG	RENE DANIEL et al., Retroviral Transfer of Antisense Sequences Results in Reduction of C-Abl and Induction of Apoptosis in Hemopoietic Cells, Journal of Biomedical Science, 1998, Vol. 5, pp. 383-394.	
	AH	QUINN L. DEVERAUX et al., Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases, The EMBO Journal, 1999, Vol. 18, No. 19, pp. 5242-5251.	
	AI	AIMEE L. EDINGER et al., Use of GPR1, GPR15, and STRL33 as Coreceptors by Diverse Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus Envelope Proteins, Virology, 1998, Vol. 249, pp. 367-378.	
	AJ	MICHAEL F. GIBLIN et al., Design and characterization of Alpha-Melanotropin peptide analogs cyclized through rhodium and technetium metal coordination, Proc. Natl. Acad. Sci. USA, October 1998, Vol. 95, pp. 12814-12818.	
	AK	GRISCELLI F. et al., Heart-specific targeting of beta-galactosidase by the ventricle-specific cardiac myosin light chain 2 promoter using adenovirus vectors, Hum. Gene Ther., September 1, 1998, Vol. 9, No. 13, pp. 1919-1928.	
	AL	M. GUANG-LIN et al., Adenovirus-Mediated Gene Transfer of CTLA4IG Gene Results in Prolonged Survival of Heart Allograft, Transplantation Proceedings, 1998, Vol. 30, pp. 2923-2924.	

Examiner Signature	/Ely Gerald Stoica/	Date Considered	05/20/2008
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.G.S.



PTO/SB/088 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3

of 7

## Complete if Known

Application Number	10/559,639
Filing Date	July 24, 2006
First Named Inventor	Dina BEN-YEHUDA
Art Unit	1647
Examiner Name	Ely Gerald STOICA
Attorney Docket Number	7640-X06-046

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AM	GUERRA PI et al., PEGylation prevents the N-terminal degradation of megakaryocyte growth and development, Pharmaceutical Research, December 1998, Vol. 15, No. 12, pp. 1822-1827.	
	AN	RAMESH HEGDE et al., Identification of Omi/HtrA2 as a Mitochondrial Apoptotic Serine Protease That Disrupts Inhibitor of Apoptosis Protein-Caspase Interaction, The Journal of Biological Chemistry, January 4, 2002, Vol. 277, No. 1, pp. 432-438.	
	AO	HEMMI S. et al., The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma, Human Gene Therapy, November 1, 1998, Vol. 9, No. 16, pp. 2363-2373.	
	AP	YIHUA HUANG et al., Structural Basis of Caspase Inhibition by XIAP: Differential Roles of the Linker versus the BIR Domain, Cell, March 9, 2001, Vol. 104, pp. 781-790.	
	AQ	HIDEYUKI IKEDA et al., Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor, Immunity, February 1997, Vol. 6, pp. 199-208.	
	AR	VERONIKA JESENBERGER et al., Deadly Encounter: Ubiquitin Meets Apoptosis, Nature Reviews Molecular Cell Biology, February 2002, Vol. 3, pp. 112-121.	
	AS	GARY M. KASOF et al., Livin, a Novel Inhibitor of Apoptosis Protein Family Member, The Journal of Biological Chemistry, February 2, 2001, Vol. 276, No. 5, pp. 3238-3246.	
	AT	ERIC C. LACASSE et al., The Inhibitors of apoptosis (IAPs) and their emerging role in cancer, Oncogene, 1998, Vol. 17, pp. 3247-3259.	
	AU	LEHMANN F. et al., Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection, European Journal of Immunology, February 1995, Vol. 25, No. 2, pp. 340-347.	
	AV	LIMAL D. et al., Solid-phase synthesis and on-resin cyclization of a disulfide bond peptide and lactam analogues corresponding to the major antigenic site of HIV gp41 protein, The Journal of Peptide Research, August 1998, Vol. 52, No. 2, pp. 121-129.	

Examiner Signature	/Ely Gerald Stoica/	Date Considered	05/20/2008
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.G.S



PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

USPS Form for form 1449/PTO

**Complete if Known****INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4

of

7

Application Number 10/559,639

Filing Date July 24, 2006

First Named Inventor Dina BEN-YEHUDA

Art Unit 1647

Examiner Name Elly Gerald STOICA

Attorney Docket Number 7640-X06-046

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AW	JIING-HUEY LIN et al., KIAP, a Novel Member of the Inhibitor of Apoptosis Protein Family, Biochemical and Biophysical Research Communications, November 22, 2000, Vol. 279, pp. 820-831.	
	AX	LOO DT et al., Measurement of cell death, Methods in Cell Biology, 1998, Vol. 57, pp. 251-264.	
	AY	M. LOTEM et al., Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV), British Journal of Cancer, 2002, Vol. 86, pp. 1534-4539.	
	AZ	OFER MANDELBOIM et al., Protection from Lysis by Natural Killer Cells of Group 1 and 2 Specificity Is Mediated by Residue 80 in Human Histocompatibility Leukocyte Antigen C Alleles and Also Occurs with Empty Major Histocompatibility Complex Molecules, J. Exp. Med., September 1996, Vol. 184, pp. 913-922.	
	BA	MARK P. MATTSON, Apoptosis in Neurodegenerative Disorders, Nature Reviews Molecular Cell Biology, October 2000, Vol. 1, pp. 120-129.	
	BB	SHOZO MURANISHI et al., Lipophilic Peptides: Synthesis of Lauroyl Thyrotropin-Releasing Hormone and Its Biological Activity, Pharmaceutical Research, 1991, Vol. 8, No. 5, pp. 649-652.	
	BC	KO NARUMI et al., Adenovirus Vector-Mediated Perforin Expression Driven by a Glucocorticoid-Inducible Promoter Inhibits Tumor Growth In Vivo, American Journal of Respiratory Cell and Molecular Biology, 1998, Vol. 19, pp. 936-941.	
	BD	NISHIDA K. et al., Adenovirus-mediated gene transfer to nucleus pulposus cells. Implications for the treatment of intervertebral disc degeneration, Spine, November 15, 1998, Vol. 23, No. 22, pp. 2437-2442.	
	BE	PANZONE G. et al., A novel glycopeptide carrying a 3-oxazolin-5-one ring obtained by intra-molecular cyclization, J. Antibiot., September 1998, Vol. 51, No. 9, pp. 872-879.	
	BF	PATEL G. et al., A cyclic peptide analogue of the loop III region of platelet-derived growth factor-BB is a synthetic antigen for the native protein, J. Pept. Res., January 1999, Vol. 53, No. 1, pp. 68-74.	

Examiner  
Signature

/Elly Gerald Stoica/

Date  
Considered

05/20/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.G.S



Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 5 of 7

## **Complete if Known**

Application Number	10/559,639
Filing Date	July 24, 2006
First Named Inventor	Dina BEN-YEHUDA
Art Unit	1647
Examiner Name	Ely Gerald STOICA
Attorney Docket Number	7640-X06-046

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BG	LEE C. PEDERSON et al., Combined Cytosine Deaminase Expression, 5-Fluorocytosine Exposure, and Radiotherapy Increases Cytotoxicity to Cholangiocarcinoma Cells, Journal of gastrointestinal Surgery, 1998, Vol. 2, pp. 283-291.	
	BH	ANGEL PORCADOR et al., Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: Implications for cancer immunotherapy, Proc. Natl. Acad. Sci. USA, November 1997, Vol. 94, pp. 13140-13145.	
	BI	JEFFREY C. RATHMELL et al., Pathways of Apoptosis in Lymphocyte Development, Homeostasis, and Disease, Cell, April 2002, Vol. 109, pp. S98-S107.	
EGS	BJ	REED CJ, Apoptosis and cancer: strategies for integrating programmed cell death, Seminars in Hematology, Vol. 37, 4 Suppl. 7, pp. 9-16. 2000	
	BK	REISSMANN S. et al., Design, synthesis and characterization of bradykinin antagonists via cyclization of the modified backbone, Biomedical Pept. Proteins Nucleic Acids, 1994-1995, Vol. 1, pp. 51-56.	
	BL	STEFAN J. RIEDL et al., Structural Basis for the Inhibition of Caspase-3 by XIAP, Cell, March 9, 2001, Vol. 104, pp. 791-800.	
	BM	JEAN RIVIER et al., Astressin Analogues (Corticotropin-Releasing Factor Antagonists) with Extended Duration of Action in the Rat, Journal of Medicinal Chemistry, 1998, Vol. 41, No. 25, pp. 5012-5019.	
	BN	ROMANOVSKIS P. et al., Preparation of head-to-tail cyclic peptides via sidechain attachment: implications for library synthesis, J. Pept. Res., November 1998, Vol. 52, No. 5, pp. 356-374.	
	BO	GUY S. SALVESEN et al., IAP Proteins: Blocking the Road to Death's Door, Nature Reviews Molecular Cell Biology, June 2002, Vol. 3, pp. 401-410.	
	BP	PAUL SCHWARZENBERGER et al., IL-17 Stimulates Granulopoiesis in Mice: Use of an Alternate, Novel Gene Therapy-Derived Method for in Vivo Evaluation of Cytokines, The Journal of Immunology, 1998, Vol. 161, pp. 6383-6389.	

Examiner Signature	/Ely Gerald Stoica/	Date Considered	05/20/2008
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.G.S



Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Application Number</b>	10/559,639
		<b>Filing Date</b>	July 24, 2006
		<b>First Named Inventor</b>	Dina BEN-YEHUDA
		<b>Art Unit</b>	1647
		<b>Examiner Name</b>	Ely Gerald STOICA
<b>Sheet</b> 6 <b>of</b> 7	<b>Attorney Docket Number</b>		7640-X06-046

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BQ	SOMMARY SOUKHAREUN et al., Use of Nalpa-Fmoc-cysteine (S-thiobutyl) Derivatized Oligodeoxynucleotides for the Preparation of Oligodeoxynucleotide - Peptide Hybrid Molecules, Bioconjugate Chem., 1998, Vol. 9, pp. 466-475.	
	BR	HENNING R. STENNICKE et al., Internally quenched fluorescent peptide substrates disclose the subsite preferences of human caspases 1, 3, 6, 7, and 8, Biochemical J., 2000, Vol. 350, pp. 563-568.	
	BS	YASUYUKI SUZUKI et al., X-linked Inhibitor of Apoptosis Protein (XIAP) Inhibits Caspase-3 and -7 Distinct Modes, The Journal of Biological Chemistry, July 20, 2001, Vol. 276, No. 29, pp. 27058-27063.	
	BT	RYOSUKE TAKAHASHI et al., A Single BIR Domain of XIAP Sufficient for Inhibiting Caspases, The Journal of Biological Chemistry, April 3, 1998, Vol. 273, No. 14, pp. 7787-7790.	
	BU	GERRARD TEOH et al., Adenovirus Vector- Based Purging of Multiple Myeloma Cells, Blood, December 15, 1998, Vol. 92, No. 12, pp. 4591-4601.	
	BV	NANCY A. THORNBERRY et al., A Combinatorial Approach Defines Specificities of Members of the Caspase Family and Granzyme B, The Journal of Biological Chemistry, July 18, 1997, Vol. 272, No. 29, pp. 17907-17911.	
	BW	VALERO ML et al., A comparative study of cyclization strategies applied to the synthesis of head-to-tail cyclic analogs of a viral epitope, J. Pept. Res., January 1999, Vol. 53, No.1, pp. 56-67.	
	BX	DOMAGOJ VUCIC et al., ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas, Current Biology, 2000, Vol. 10, pp. 1359-1366.	
	BY	DOMAGOJ VUCIC et al., SMAC Negatively Regulates the Anti-apoptotic Activity of Melanoma Inhibitor of Apoptosis (ML-IAP), The Journal of Biological Chemistry, April 5, 2002, Vol. 277, pp. 12275-12279.	
	BZ	SUSAN WANG et al., Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells, Journal of Controlled Release, 1998, Vol. 53, pp. 39-48.	

<b>Examiner Signature</b>	/Ely Gerald Stoica/	<b>Date Considered</b>	05/20/2008
---------------------------	---------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.G.S



PTO/ISB/088 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	10/559,639
Filing Date	July 24, 2006
First Named Inventor	Dina BEN-YEHUDA
Art Unit	1647
Examiner Name	Elly Gerald STOICA
Attorney Docket Number	7640-X06-046

Sheet 7 of 7

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	JANICE WHITE et al., Soluble Class I MHC with Beta2-Microglobulin Covalently Linked Peptides: Specific Binding to a T Cell Hybridoma, The Journal of Immunology, 1999, Vol. 162, pp. 2671-2676.	
	CB	YILI YANG et al., Ubiquitin Protein Ligase Activity of IAPs and Their Degradation in Proteasomes in Response to Apoptotic Stimuli, Science, May 5, 2000, Vol. 288, pp. 874-877.	
	CC	CHONGXI YU et al., Synthesis and Study of Peptides with Semirigid i and i + 7 Side-chain Bridges Designed for Alpha-Helix Stabilization, Bioorganic & Medical Chemistry, 1999, Vol. 7, pp. 161-175.	
	CD	ZACHARIA S. et al., New reduced peptide bond substance P agonists and antagonists: effects on smooth muscle contraction, Eur. J. Pharmacol., October 22, 1991, Vol. 203, No. 3, pp. 353-357.	
	CE	SHENGLE ZHANG et al., Selection of Tumor Antigens as Targets for Immune Attack Using Immunohistochemistry: Protein Antigens, Clinical Cancer Research, November 1998, Vol. 4, pp. 2669-2676.	
	CF	DATABASE EMBL BIR7 sequence (28Feb2003) XP002296040 Database accession No. Q96CA5.	
	CG	M. GERMANA SANNA et al., IAP Suppression of Apoptosis Involves Distinct Mechanisms: the TAK1/JNK1 Signaling Cascade and Caspase Inhibition, Molecular and cellular Biology, March 2002, Vol. 22, No. 6, pp 1754-1766.	

Examiner Signature	/Elly Gerald Stoica/	Date Considered	05/20/2008
--------------------	----------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.G.S